pull down to refresh
100 sats \ 3 replies \ @dontforgetthekeys OP 11 Aug \ parent \ on: The Benefits of Ozempic Are Multiplying science
woah blind, you got a link?
definitely a devil's deal:
lose weight, but go blind. finally look the way you wanted, but you can't see it. lol!
Just googled and it's the first I'm seeing the article, I had only heard about it, but Mass Eye and Ear is in my old stomping ground which might be why it came to mind
reply
I'm going to dig into this one later. It read like a fluff piece for their doctors and hospitals.
the two things that stood out to me:
- they did the study backwards: when you do that you're usually bias to find what you want to find.
-
There are several limitations to the study. Mass Eye and Ear sees an unusually high number of people with rare eye diseases, the study population is majority white, and the number of NAION cases seen over the six-year study period is relatively small. With small case numbers, statistics can change quickly, Rizzo noted. The researchers also couldn't determine if the patients actually took their medication or if they started and then stopped taking semaglutide at some point and how this might have impacted their risk.
I'm not saying they are wrong. I just want to spend more time figuring our where the correlation is and how does one get this rare NAION condition in the first place.
reply
Yea its not like a typical study it started off anecdotal...
MassGen is an elite facility and I wouldn't expect a marketing or a fishing expedition out of them, rather the opposite as they're adjacent to that Cambridge Biotech Capital sphere that's marketing the drugs... Maybe hospitals are being more proactive after the C19 stuff...
reply